Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 6,846 matching trials from the live ClinicalTrials.gov search.
Filters: Orlando, Florida Clear all
Recruiting Phase 1Phase 2 Interventional

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

NCT05874414
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
GNS561 + Trametinib
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Results available

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

NCT01864174
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT05557409
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Peoria, Arizona • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 11:37 PM EDT
Completed No phase listed Observational

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

NCT00996047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
3,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2012
U.S. locations
280
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 30, 2026, 11:37 PM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
Interventions
Ceritinib, Docetaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Adults With or Without Kidney Problems

NCT05992155
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 30, 2026, 11:37 PM EDT
Enrolling by invitation Phase 3 Interventional

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

NCT05905926
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
27
States / cities
Foley, Alabama • Anaheim, California • Doral, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 11:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).

NCT04154878
View directory record Official record
Conditions
Diastolic Heart Failure, Left Ventricular Diastolic Dysfunction, Left Ventricular Diastolic Collapse
Interventions
Not listed
Lead sponsor
AdventHealth
Other
Eligibility
45 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

NCT03033576
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Mucosal Melanoma, Unresectable Cutaneous Melanoma, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
638
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 392 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

NCT05586971
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Allopurinol, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
124
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

NCT02001571
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia

NCT00003671
View directory record Official record
Conditions
Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
50
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo

NCT00762411
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY450139, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Costa Mesa, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 30, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement

NCT00403234
View directory record Official record
Conditions
Postoperative Pain
Interventions
Buprenorphine transdermal patch, Placebo BTDS
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Phoenix, Arizona • San Clemente, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Tucson, Arizona • Beverly Hills, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Maximizing Outcomes in Treating Acute Migraine

NCT03896009
View directory record Official record
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 30, 2026, 11:37 PM EDT
Recruiting Phase 2 Interventional

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT06847321
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Interventions
LHP588, Placebo Drug
Drug
Lead sponsor
Lighthouse Pharmaceuticals, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Murrieta, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT00566449
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, JNJ-31001074
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Irvine, California • Lafayette, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Results available

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

NCT02819726
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAIT101, MabThera, Rituxan
Biological
Lead sponsor
Archigen Biotech Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Anniston, Alabama • El Cajon, California • La Mesa, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 30, 2026, 11:37 PM EDT
Completed No phase listed Observational

Donor Breast Milk and Serum Ferritin Levels in Very Preterm Infants

NCT06843278
View directory record Official record
Conditions
Ferritin Levels in Very Preterm Infants
Interventions
maternal breast milk, Donor breast milk
Other
Lead sponsor
AdventHealth
Other
Eligibility
2 Weeks to 4 Weeks
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

NCT00042068
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Meloxicam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
72
States / cities
Huntsville, Alabama • Montgomery, Alabama • Anchorage, Alaska + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

NCT00160693
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
29
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
12
States / cities
Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00742625
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
Interventions
daunorubicin hydrochloride, cytarabine, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years to 75 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Orlando, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 30, 2026, 11:37 PM EDT